Form D · Biotechnology
Medicenna Therapeutics Corp.
Toronto, A6 · CIK 0001807983
Offering snapshot reported Jul 6, 2026 · SEC filing
- Reported sold
- $253K Offering amount: $2.34M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 28, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 6, 2026 | Initial | $253,458 | No comparison | 3 | SEC filing |
| May 14, 2024 | Initial | $14,550,000 | No comparison | 1 | SEC filing |
| Apr 20, 2020 | Amendment | $9,219,339 | $2,501,797vs Mar 30, 2020 | 6 | SEC filing |
| Mar 30, 2020 | Initial | $6,717,542 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-589660
The additional $2,089,942 may be received upon the exercise of common share purchase warrants if exercised in the U.S. U.S. dollar amounts based on the Bank of Canada average rate of exchange reported on May 28, 2026, which was CDN$1.3809 =US$1.00.
Each Unit is comprised of 1 common share and 1/2 of 1 common share purchase warrant. Each Warrant entitles the holder thereof to purchase one additional Share at an exercise price of CDN$0.65 per Share for a period of 3 years following May 28, 2026.
Source: Form D, filed Jul 6, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Albert G. Beraldo | Director |
| Karen Dawes | Director |
| John Geltosky | Director |
| Angelos Georgakis | Director |
| David Hyman | Executive |
| Nageatte Ibrahim | Executive |
| Karim Lalji | Director |
| Fahar Merchant | Director, Executive |
| Rosemina Merchant | Executive |
| Chandra Panchal | Director |
| John Sampson | Director |
| Andrew Strong | Director |
| Richard Sutin | Director |
| Elizabeth Williams | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2 Bloor Street W Suite 903
Toronto, A6, M4W 3E2
Phone: 604-671-6673
Toronto, A6, M4W 3E2
Phone: 604-671-6673